These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 52054

  • 1. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
    Barbeau A.
    Lancet; 1975 Oct 11; 2(7937):683-4. PubMed ID: 52054
    [Abstract] [Full Text] [Related]

  • 2. Active and inactive L-prolyl-L-leucyl glycinamide synthetic analogs in rat models of levodopa-treated Parkinson's disease.
    Case TC, Snider SR, Hruby VJ, Rockway T.
    Life Sci; 1985 Jul 01; 36(26):2531-7. PubMed ID: 2861549
    [Abstract] [Full Text] [Related]

  • 3. Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
    Kastin AJ, Barbeau A.
    Can Med Assoc J; 1972 Dec 09; 107(11):1079-81. PubMed ID: 4640811
    [Abstract] [Full Text] [Related]

  • 4. [Physiological trials with MIF-I in Parkinson's disease (author's transl)].
    Gonce M, Barbeau A.
    Rev Neurol (Paris); 1978 Feb 09; 134(2):141-9. PubMed ID: 29330
    [Abstract] [Full Text] [Related]

  • 5. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
    Pan JB.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug 09; 18(4):205-8. PubMed ID: 2866940
    [No Abstract] [Full Text] [Related]

  • 6. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ.
    Mov Disord; 2007 Apr 15; 22(5):715-9. PubMed ID: 17373723
    [Abstract] [Full Text] [Related]

  • 7. L-dopa potentiating analogs of Pro-Leu-Gly-NH2 with oral efficacy.
    Albrecht HP, Hofman HP, Klebe G, Kreiskott H.
    Boll Chim Farm; 1991 Feb 15; 130(2):55-9. PubMed ID: 1678611
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
    Xu DL, Yu WC, Pan GB, Chen SD.
    Adv Neurol; 1987 Feb 15; 45():587-90. PubMed ID: 2881450
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide.
    Kostrzewa RM, Kastin AJ, Sobrian SK.
    Pharmacol Biochem Behav; 1978 Sep 15; 9(3):375-8. PubMed ID: 30981
    [Abstract] [Full Text] [Related]

  • 10. Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.
    Barbeau A, Roy M, Kastin AJ.
    Can Med Assoc J; 1976 Jan 24; 114(2):120-2. PubMed ID: 3279
    [Abstract] [Full Text] [Related]

  • 11. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.
    Kurth MC.
    Drugs Aging; 1997 May 24; 10(5):332-40. PubMed ID: 9143854
    [Abstract] [Full Text] [Related]

  • 12. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP.
    Prog Brain Res; 1975 May 24; 42():11-23. PubMed ID: 730
    [No Abstract] [Full Text] [Related]

  • 13. Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered.
    Chaná P, Kuntsmann C, Reyes-Parada M, Sáez-Briones P.
    J Neurol Neurosurg Psychiatry; 2004 Dec 24; 75(12):1782-3. PubMed ID: 15548507
    [No Abstract] [Full Text] [Related]

  • 14. Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.
    Caraceni T, Parati EA, Girotti F, Celano I, Frigerio C, Cocchi D, Müller EE.
    Psychopharmacology (Berl); 1979 Jun 21; 63(3):217-22. PubMed ID: 39308
    [Abstract] [Full Text] [Related]

  • 15. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC, Mena I, Papavasiliou PS, Mendez J.
    Adv Neurol; 1974 Jun 21; 5():295-9. PubMed ID: 4440577
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacological studies with a tripeptide, prolyl-leucyl glycine amide.
    Plotnikoff NP, Kastin AJ.
    Arch Int Pharmacodyn Ther; 1974 Oct 21; 211(2):211-24. PubMed ID: 4156639
    [No Abstract] [Full Text] [Related]

  • 17. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL, Smissman EE, Plotnikoff NP.
    J Med Chem; 1978 Feb 21; 21(2):165-9. PubMed ID: 23433
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM, Heuser IJ, Baronti F, Giuffra M, Conant K, Davis TL, Chase TN.
    J Neurol Neurosurg Psychiatry; 1991 May 21; 54(5):401-5. PubMed ID: 1865201
    [Abstract] [Full Text] [Related]

  • 19. Effects of levodopa infusion on motor activation responses in Parkinson's disease.
    Feigin A, Ghilardi MF, Fukuda M, Mentis MJ, Dhawan V, Barnes A, Ghez CP, Eidelberg D.
    Neurology; 2002 Jul 23; 59(2):220-6. PubMed ID: 12136061
    [Abstract] [Full Text] [Related]

  • 20. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F, Rabey JM.
    Eur J Neurol; 2011 Dec 23; 18(12):1373-8. PubMed ID: 21895884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.